Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
38 results about "Megakaryocyte Progenitor Cells" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The parent cells that give rise to cells in the MEGAKARYOCYTE lineage, and ultimately BLOOD PLATELETS.
Methods for in vitro expansion of hematopoietic stem cells
InactiveUS20050276793A1Useful in therapyBiocideArtificial cell constructsProgenitorMegakaryocyte Progenitor Cells
The invention relates to methods of obtaining compositions for generating multipotent hematopoietic stem progenitor cells comprising expansion of hematopoietic stem cells in the presence of HDACI and IDM. Methods of obtaining compositions enriched in hematopoietic megakaryocyte progenitor cells are also provided. Compositions enriched for stem cells and populations of cells obtained therefrom are also provided by the invention.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS
Cell cryopreservation liquid, application thereof and cryopreservation method of megakaryocyte progenitor cells
ActiveCN105076116AVitality has little effectReduce harmDead animal preservationCryopreservationCellular viability
The invention relates to the field of cell culture, in particular to cell cryopreservation liquid, application thereof and a cryopreservation method of megakaryocyte progenitor cells. The cell cryopreservation liquid comprises DMSO, fetal calf serum, dextran, trehalose and albumin. By means of the cell cryopreservation liquid, the cytoactive of the megakaryocyte progenitor cells can be well maintained during the cryopreservation period, and damage to cells in the cryopreservation and resuscitation processes is lowered. According to the cell cryopreservation liquid, application thereof and the cryopreservation method of the megakaryocyte progenitor cells, the cryopreservation and temperature reduction processes are softer, the cells are stored in liquid nitrogen after the temperature reduction process is conducted, the influence on the cytoactive is small, and damage to the cells in the cryopreservation process is lowered. It is indicated by experiments that the vigour of the resuscitated cells can reach 94% one month after the megakaryocyte progenitor cells are cryopreservated in the cryopreservation liquid, and multiplication activity is good, and the cell cryopreservation liquid is significantly superior to the prior art.
Owner:GUANGZHOU SALIAI STEMCELL SCI & TECH CO LTD
Mammalian megakaryocyte progenitor cell
A substantially enriched mammalian hematopoietic cell population is provided, which is characterized as a progenitor cell committed to the megakaryocyte lineage. Methods are provided for the isolation and culture of these cells. The cell enrichment methods employ reagents that specifically recognize CD9 and CD41, in conjunction with other markers expressed on lineage committed progenitor cells. These cells give rise exclusively to megakaryocytes and platelets, as evidenced by their growth and differentiation in vitro and in vivo.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Method for inducing megakaryoblast and megakaryocyte in vitro
ActiveCN101864396AHigh yieldImprove settlement efficiencyCulture processBlood/immune system cellsFicollSerum free media
The invention discloses a method for inducing megakaryoblast and megakaryocyte in vitro and a special culture medium thereof. The special culture medium is a serum free medium containing 50ng / mL of SCF, 50ng / mL of TPO, 20ng / mL of IL-3 and 50ng / mL of IL-6. The method comprises the following steps of: 1) separating single karyocyte from umbilical cord blood by using the conventional Ficoll density gradient centrifugation method, wherein red blood cells in the umbilical cord blood are settled by 6 percent hydroxyethyl starch; and 2) culturing the single karyocyte in vitro for 4 to 14 days by using the special culture medium at 37 DEG C in the presence of 5 percent CO2 to obtain a mixture of the megakaryoblast and the megakaryocyte. The invention provides a source for supplementing the megakaryoblast and the megakaryocyte, and has the advantages of simple operation, low cost, high differentiation efficiency and the like. The method is about to play an important role in the field of medicaments, and has wide application prospect.
Owner:FIELD OPERATION BLOOD TRANSFUSION INST OF PLA SCI ACAD OF MILITARY
Methods for in vitro expansion of hematopoietic stem cells
The invention relates to methods of obtaining compositions for generating multipotent hematopoietic stem progenitor cells comprising expansion of hematopoietic stem cells in the presence of HDACI and IDM. Methods of obtaining compositions enriched in hematopoietic megakaryocyte progenitor cells are also provided. Compositions enriched for stem cells and populations of cells obtained therefrom are also provided by the invention.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS
Agonist antibodies
InactiveUS20050208585A1Improve and modulate half-lifePeptide librariesImmunoglobulins against cytokines/lymphokines/interferonsAgonistMegakaryocyte Progenitor Cells
Various forms of c-mpl agonist antibodies are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.
Owner:ADAMS CAMELLIA +3
Megakaryocyte progenitor cells for production of platelets
Provided herein are methods of generating megakaryocyte lineage cells from hematopoietic stem cells in the absence of feeder cells and serum. The megakaryocyte progenitor cells (MKPs) generated as described result in rapid production of significant numbers of platelets when administered in vivo.
Owner:CELLERANT THERAPEUTICS INC
Method for increasing directional differentiation quantity of cord blood megakaryoblasts
ActiveCN104789530AIncrease the number of directed differentiationImprove securityBlood/immune system cellsCord blood stem cellCytokine
The invention discloses a method for increasing the directional differentiation quantity of cord blood megakaryoblasts. The method comprises the step of carrying out directional differentiation on cord blood hematopoietic stem cells serving as specimen cells in a specific culture medium containing resveratrol. Due to the adoption of the specific culture medium containing resveratrol, the operation for directional differentiation of megakaryoblasts becomes simpler, more convenient, safer and more efficient. Resveratrol is added while cell factors are added in the directional differentiation culture process from the cord blood hematopoietic stem cells to the megakaryoblasts, so that the effect of increasing the quantity of the generated megakaryoblasts is achieved. The method is simple and convenient to operate and low in cost, and the obtained megakaryoblasts are high in safety.
Owner:广州市天河诺亚生物工程有限公司
Method for improving efficiency of differentiation induced in vitro of cord blood megakaryocyte progenitor cells
ActiveCN105062969AImprove the efficiency of directed differentiationHigh purityBlood/immune system cellsCord blood stem cellStem cell culture
The invention belongs to the technical field of cells and particularly relates to a method for improving efficiency of differentiation induced in vitro of cord blood megakaryocyte progenitor cells. The method provided by the invention comprises the following steps: adding a type I stem cell culture medium containing 50mu mol / L resveratrol into cord blood total nucleated cells for culturing for 72 hours, and then changing a type II stem cell culture medium free of resveratrol for further culturing, thereby obviously improving the efficiency of differentiation of megakaryocyte progenitor cells. According to the invention, the type I stem cell culture medium containing 50mu mol / L resveratrol is firstly used for culturing, and then the type II stem cell culture medium free of resveratrol is used for for further culturing; according to the culture sequence of the two culture mediums, the efficiency of directional differentiation of cord blood hematopoietic stem cells to megakaryocyte progenitor cells can be obviously improved, and megakaryocyte progenitor cells with high purity can be prepared. The method is simple and reliable in process, good in repeatability, low in possibility of pollution as well as economical in preparation cost and safe in operation.
Owner:广州市天河诺亚生物工程有限公司
Delivery vehicle for recombinant proteins
Recombinant nucleic acid molecules are constructed with a first sequence encoding a transgene under the control of regulatory sequences that direct expression of the transgene product in a hematopoietic stem cell, or a progenitor cell therefrom or cell differentiated therefrom. In one embodiment, the cell which expresses the transgene is a secretory cell. The cell is a megakaryotic progenitor cell, or a cell further differentiated therefrom, such as a platelet. The cell is a granulocyte / macrophage progenitor cell or a cell further differentiated therefrom, such as a mast cell or neutrophils. Such host cells containing the molecule or the molecule itself are employed in methods for treating or preventing infection, inflammation or vascular injuries or any disorders involving or mediated by cells of the hematopoietic lineage.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA +1
Method for preparing megakaryocytic preparation by amplifying macronucleus ancestral cell and mature megacaryocyte and use
The present invention relates to mainly one system of efficient culturing and directive inducing stem cell differentiation for culturing and proliferating megakaryocyte. The system has umbilical cord blood and marrow stem cell as seed cell, and the serum-free culture medium comprising TPO, IL-11 and heparin as the main component for megakaryocyte proliferation. The megakaryocyte preparation prepared based on the present invention contains great amount of macronucleus ancestral cells and mature megakaryocyte as well as CD34+ cells, and has the functions of treating thrombocytopenia and improving the blood-forming function after stem cell transplantation. The present invention provides novel efficient cell treating preparation for various thrombocytopenia and hemocyitopenia.
Owner:INST OF HEMATOLOGY & BLOOD HOSPITAL CHINESE ACAD OF MEDICAL SCI
Megakaryocyte progenitor cell cryopreservation solution and application thereof
The invention discloses a megakaryocyte progenitor cell cryopreservation solution and application thereof. The megakaryocyte progenitor cell cryopreservation solution comprises DMSO (Dimethylsulfoxide) and blood plasma. The cryopreservation solution can be effectively used for cryopreserving megakaryocyte progenitor cells; after cell recovery, the survival rate and the recovery rate are high.
Owner:ACADEMY OF MILITARY MEDICAL SCI +1
Separation method for megakaryocyte progenitors
The invention relates to the field of cell culture, in particular to a separation method for megakaryocyte progenitors. According to the method, stimulation culturing is performed on single karyocytes obtained through separation through rhG-CSFs, so that the content of megakaryocytes in the cells is increased, the cells processed through stimulation culturing are screened with immunomagnetic beads, and the megakaryocyte progenitors are obtained. The megakaryocyte progenitors are isolated by adopting the method, the yield is higher, and the number of the megakaryocytes (the phenotype is CD41a<+> / CD61<+>) obtained through induced directional differentiation is larger. Experiments show that 20-100 mL of umbilical cord blood is separated through the method, the number of the obtained megakaryocyte progenitors can reach 2.75*10<6>, the quantity percentage of the megakaryocytes in the obtained cells is 5%-10%, and after 14 days of induced directional differentiation, the total number of the megakaryocytes can be amplified by 132.5+ / -21.2 times, and the proportion of the megakaryocytes can reach 81%.
Owner:GUANGZHOU SALIAI STEMCELL SCI & TECH CO LTD
Mammalian megakaryocyte progenitor cell
A substantially enriched mammalian hematopoietic cell population is provided, which is characterized as a progenitor cell committed to the megakaryocyte lineage. Methods are provided for the isolation and culture of these cells. The cell enrichment methods employ reagents that specifically recognize CD9 and CD41, in conjunction with other markers expressed on lineage committed progenitor cells. These cells give rise exclusively to megakaryocytes and platelets, as evidenced by their growth and differentiation in vitro and in vivo.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Induction method of megakaryocyte progenitor cells
ActiveCN109022361AImprove the efficiency of induced differentiationImprove efficiencySkeletal/connective tissue cellsBlood/immune system cellsCord blood stem cellMesenchymal stem cell
The invention discloses an induction method of megakaryocyte progenitor cells. The method includes: isolating and screening cord blood CD34+CD126- cells; isolating and culturing umbilical cord mesenchymal stem cells; co-culturing the cord blood CD34+CD126- cells with the umbilical cord mesenchymal stem cells, and conducting amplification and induced differentiation of megakaryocyte progenitor cells. The induction method of megakaryocyte progenitor cells provided by the invention performs isolation and screening of cord blood CD34+CD126- cells and adopts the way of co-culture with the umbilicalcord mesenchymal stem cells for induced differentiation of megakaryocyte progenitor cells, increases the induced differentiation efficiency of in vitro megakaryocyte progenitor cells, and also enhances the amplification efficiency.
Owner:HUZHOU COLLEGE +1
Cell preservation liquid and application thereof in protecting megakaryocyte progenitor cell activity
The invention relates to the field of cell culture, in particular to cell preservation liquid and application thereof in protecting megakaryocyte progenitor cell activity. The cell preservation liquid comprises water, folic acid, albumin, an astragalus extract and sodium chloride. The cell preservation liquid can provide corresponding nutrients for cells in the preservation process, so that the activity of the cells is maintained, and the cells are not likely to be gathered or died. More preservation liquid can be provided for preserving the megakaryocyte progenitor cells, the cell activity can be kept at about 90% within 24 h, the cell preservation liquid is obviously better than a control group in which normal saline or the mixture of normal saline and albumin is adopted, and it proves that the preservation liquid can achieve the effect of well protecting the megakaryocyte progenitor cell activity.
Owner:GUANGZHOU SALIAI STEMCELL SCI & TECH CO LTD
In-vitro culture method of umbilical cord blood megakaryocyte progenitor cells
InactiveCN106479976AEnhance progenitor cell identityImprove the ability to differentiate into plateletsCell culture mediaBlood/immune system cellsSerum free mediaPlatelet
The invention discloses an in-vitro culture method of umbilical cord blood megakaryocyte progenitor cells. According to the method, a specific megakaryocyte progenitor cell medium is inoculated with umbilical blood cells for culture. The specific megakaryocyte progenitor cell medium is a serum-free medium containing 40vol%-50vol% of hematopoietic stem cell culture supernatant, 50+ / -10 ng / mL SCF and 50+ / -10 ng / mL TPO, wherein the hematopoietic stem cell culture supernatant is obtained by culturing umbilical cord blood hematopoietic stem cells in a serum-free medium containing IL-6, IL-3, SCF, Flt-3L and TPO for 3-4 days. With the adoption of the method, the progenitor cell characteristics of umbilical cord blood megakaryocyte progenitor cells realizing in-vitro amplification are effectively improved, the megakaryocyte progenitor cell obtaining efficiency is improved, and accordingly, the capacity of the megakaryocyte progenitor cells differentiating into blood platelet is improved. In the amplification stage of the megakaryocyte progenitor cells, the consumption of added cell factors is reduced, accordingly, material consumption is reduced, and the cost is reduced.
Owner:浙江绿蔻生物技术有限公司
Method for amplifying megakaryocyte progenitor cell from human cord blood CD34<+> cell
Owner:INST OF HEMATOLOGY & BLOOD HOSPITAL CHINESE ACAD OF MEDICAL SCI
A cell culture medium and its application in culturing megakaryotic progenitor cells
ActiveCN105296420BFull of nutritionPromote growthBlood/immune system cellsInterleukin 6Wnt3A Protein
The invention relates to the field of cell culture, in particular to a cell culture solution and application thereof to culture of megakaryocyte progenitor cells. According to the invention, WNT3a protein, insulin, Flt-3L, albumin, non-essential amino acid, thrombopoietin, stem cell growth factors, interleukin 3 and interleukin 6 are compounded, and a basal culture medium is added, so that richer nutrition can be provided for cells. Experiments show that the culture solution provided by the invention is used for culture of megakaryocyte progenitor cells and can selectively promote growth and proliferation of the megakaryocyte progenitor cells. After the culture solution provided by the invention cultures the megakaryocyte progenitor cells for 20 days, the number of cells is increased by 400-450 times, and the CD34+ and CD41+ double-positive expression rate in the cells is not lower than 35%. The effect is remarkably superior to that of a culture medium in the prior art (p is less than 0.01).
Owner:GUANGZHOU SALIAI STEMCELL SCI & TECH CO LTD
Megakaryotic progenitor cell cryopreservation medium and its application
Disclosed are a megakaryocyte progenitor cryopreservation liquid and the use thereof, wherein the megakaryocyte progenitor cryopreservation liquid comprises: DMSO and plasma. The cryopreservation liquid can be effectively used to cryopreserve megakaryocyte progenitors, and the survival rate and recovery rate after cell revival are high.
Owner:ACADEMY OF MILITARY MEDICAL SCI +1
A method for improving the differentiation efficiency of umbilical cord blood megakaryocyte progenitor cells in vitro
ActiveCN105062969BImprove the efficiency of directed differentiationHigh purityBlood/immune system cellsProgenitorCord blood stem cell
The invention belongs to the field of cell technology, and in particular relates to a method for improving the differentiation efficiency of umbilical cord blood megakaryocyte progenitor cells in vitro. In the present invention, the type I stem cell culture medium containing 50 μmol / L resveratrol is added to the total nucleated cells of the umbilical cord blood for 72 hours, and the type II stem cell culture medium without resveratrol is replaced to continue the culture, and finally the High differentiation efficiency of megakaryotic progenitor cells. The present invention discloses that after culturing and treatment with Type I stem cell medium containing 50 μmol / L resveratrol, and then replacing Type II stem cell medium without any resveratrol component to continue culturing, through successive cultivation of these two mediums Sequential combination can significantly improve the efficiency of directional differentiation of umbilical cord blood hematopoietic stem cells to megakaryotic progenitor cells, and can prepare megakaryotic progenitor cells with higher purity. The process of the method is simple, reliable and repeatable, the possibility of pollution is low, and the economy of the preparation cost and the operation safety are taken into consideration.
Owner:广州市天河诺亚生物工程有限公司
A kind of cell cryopreservation solution and its application and cryopreservation method of megakaryotic progenitor cells
Owner:GUANGZHOU SALIAI STEMCELL SCI & TECH CO LTD
A method for increasing the number of directional differentiation of umbilical cord blood megakaryotic progenitor cells
ActiveCN104789530BIncrease the number ofLow costBlood/immune system cellsProgenitorCord blood stem cell
The invention discloses a method for increasing the number of directional differentiation of umbilical cord blood megakaryocyte progenitor cells. In this method, umbilical cord blood hematopoietic stem cells are used as sample cells, and directed differentiation is carried out in a specific medium containing resveratrol. The specific medium containing resveratrol makes the operation of directed differentiation of megakaryotic progenitor cells easier, safer and more efficient. In the process of directional differentiation and culture of umbilical cord blood hematopoietic stem cells to megakaryotic progenitor cells, resveratrol is added together with cytokines to achieve the effect of increasing the number of megakaryotic progenitor cells. The method of the present invention is easy to operate and low in cost. Cell safety is high.
Owner:广州市天河诺亚生物工程有限公司
mpl ligand (thrombopoietin), active fragments thereof, and fusion proteins and compositions comprising mpl ligand and other cytokines
Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant or synthetic methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.
Owner:GENENTECH INC
Nucleic acids encoding MPL ligand (thrombopoietin), variants, and fragments thereof
Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant or synthetic methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.
Owner:GENENTECH INC
Method for preparing megakaryocytic preparation by amplifying macronucleus ancestral cell and mature megacaryocyte and use
The present invention relates to mainly one system of efficient culturing and directive inducing stem cell differentiation for culturing and proliferating megakaryocyte. The system has umbilical cord blood and marrow stem cell as seed cell, and the serum-free culture medium comprising TPO, IL-11 and heparin as the main component for megakaryocyte proliferation. The megakaryocyte preparation prepared based on the present invention contains great amount of macronucleus ancestral cells and mature megakaryocyte as well as CD34+ cells, and has the functions of treating thrombocytopenia and improving the blood-forming function after stem cell transplantation. The present invention provides novel efficient cell treating preparation for various thrombocytopenia and hemocyitopenia.
Owner:INST OF HEMATOLOGY & BLOOD HOSPITAL CHINESE ACAD OF MEDICAL SCI
Monoclonal antibody to human thrombopoietin
Isolated thrombopoietin (TPO), isolated DNA encoding TPO, and recombinant or synthetic methods of preparing and purifying TPO are disclosed. Various forms of TPO are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.
Owner:GENENTECH INC
A preparation of megakaryotic progenitor cells and its application and preparation method
ActiveCN105126083BSignificant improvementEasy to usePeptide/protein ingredientsUnknown materialsHuman albuminNormal level
The invention relates to the technical field of a stem cell preparation, in particular to a megakaryocyte progenitor cell preparation as well as application and a preparation method thereof. The megakaryocyte progenitor cell preparation consists of megakaryocyte progenitor cells, human albumin, a stem cell growth factor, interleukin-2 and a safflower injection. The megakaryocyte progenitor cell preparation disclosed by the invention has a significant effect on improving aleucia; after infusion, platelet content in patients, as being recovered, can be kept at a normal level for a relatively long time in vivo; and the megakaryocyte progenitor cell preparation, after being applied, is free from any adverse reaction and safe to use, and the megakaryocyte progenitor cell preparation is simple in preparation and convenient to use.
Owner:GUANGZHOU SALIAI STEMCELL SCI & TECH CO LTD
A composition for adjuvant treatment of chronic bleeding and its application
ActiveCN111053788BEfficient use ofAvoid infectionUnknown materialsBlood disorderDiseaseChronic hemorrhage
The invention discloses a composition for adjuvant treatment of chronic bleeding and its application. The composition is composed of exosomes of megakaryocyte progenitor cells and endothelial progenitor cells, and can be formulated according to different indications, which is scientific and economical. The endothelial progenitor cell exosomes used in the present invention are obtained by ultra-high-speed centrifugation of the culture medium of the endothelial progenitor cells after the endothelial progenitor cells are cultured, and the endothelial progenitor cells with more clinical therapeutic value can be reserved for other severe diseases Diseases, more comprehensive use of biological resources; the composition of the present invention is used for adjuvant treatment of chronic bleeding, taking into account blood coagulation and blood vessel repair, avoiding infection or immune rejection caused by blood transfusion, lower cost, safer, better curative effect, It is more durable and has important clinical application value.
Owner:广州市天河诺亚生物工程有限公司
Mpl ligand
Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant or synthetic methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.
Owner:GENENTECH INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com